替诺福韦对长期病毒血症控制HIV感染成人端粒、端粒酶及T细胞成熟亚群分布的影响
本研究纳入128例长期病毒血症控制的HIV感染成人,比较含替诺福韦方案(n=79)与不含替诺福韦方案(n=49)对端粒长度、端粒酶活性及T细胞成熟亚群分布的影响。调整分析显示,替诺福韦治疗至少4年者CD8+ T细胞端粒较短(P=0.04),CD4+(P=0.012)和CD8+ T细胞(P=0.023)端粒酶活性较低,且近期胸腺 emigrant(RTE)CD4+细胞比例较低(P=0.031)、PD1表达较低(P=0.013)。作者认为替诺福韦抑制端粒酶可解释CD8+ T细胞端粒缩短,CD4+区室无端粒缩短。
要点
- 替诺福韦治疗至少4年与CD8+ T细胞端粒较短相关(P=0.04)。
- 替诺福韦治疗与CD4+和CD8+ T细胞端粒酶活性较低相关(P=0.012和P=0.023)。
- 替诺福韦治疗与RTE CD4+细胞比例较低及PD1表达较低相关(P=0.031和P=0.013)。
核心结论
- 在长期病毒血症控制的HIV感染成人中,替诺福韦抑制端粒酶可解释CD8+ T细胞端粒缩短;CD4+区室无端粒缩短,端粒酶活性降低可由替诺福韦抑制及RTE CD4+细胞比例较低共同解释。
研究设计与样本
- 研究纳入128例长期病毒血症控制的HIV感染成人,其中含替诺福韦方案组79例、不含替诺福韦方案组49例。
主要发现
- 调整分析中,替诺福韦治疗至少4年者CD8+ T细胞端粒较短(P=0.04)。
- 替诺福韦治疗至少4年者CD4+ T细胞端粒酶活性较低(P=0.012),CD8+ T细胞端粒酶活性较低(P=0.023)。
- 替诺福韦治疗与RTE CD4+细胞比例较低相关(P=0.031),与PD1标志表达较低相关(P=0.013)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To evaluate whether the negative impact of tenofovir on telomere length (TL) is due to immune reconstitution interference or inhibition of telomerase. METHODS: One hundred and twenty-eight long-term aviraemic HIV adults treated with tenofovir-containing (n = 79) or tenofovir-sparing regimens (n = 49) were recruited to compare the following: TL in whole blood, PBMCs, CD4+ T cells and CD8+ T cells by quantitative PCR (qPCR); telomerase activity in PBMCs, CD4+ cells and CD8+ T cells using the TRAPeze RT Telomerase Detection Kit; and T cell maturational subset distribution by flow cytometry. RESULTS: In an adjusted analysis, participants treated with tenofovir for at least 4 years had shorter TL in CD8+ T cells (P = 0.04) and lower telomerase activity in CD4+ (P = 0.012) and CD8+ T cells (P = 0.023). Tenofovir treatment was also associated with lower proportions of recent thymic emigrant (RTE) CD4+ cells (P = 0.031) and PD1 marker expression (P = 0.013). CONCLUSIONS: In long-term aviraemic HIV adults, the inhibition of telomerase by tenofovir could explain telomere shortening in CD8+ T cells. There is no telomere shortening in the CD4+ compartment and the decrease in telomerase activity could be explained both by the inhibition by tenofovir and by the lower proportion of RTE CD4+cells.
引用
- Rodríguez-Centeno J, Esteban-Cantos A, Montejano R, et al. Effects of tenofovir on telomeres, telomerase and T cell maturational subset distribution in long-term aviraemic HIV-infected adults. J Antimicrob Chemother. 2022. PMID: 35045162. doi:10.1093/jac/dkab492
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。